Difference between revisions of "Clofarabine (Clolar)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Neutral chemotherapy" to "Category:Neutral") Tags: mobile edit mobile web edit |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Acute | + | *[[:Category:Acute lymphoblastic leukemias |Acute lymphoblastic leukemia]] |
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Myelodysplastic syndrome]] | *[[Myelodysplastic syndrome]] | ||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 12/28/2004: Initial FDA approval | + | * 12/28/2004: Initial FDA approval for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory [[:Category:Acute lymphoblastic leukemias | acute lymphoblastic leukemia]] after at least two prior regimens. |
==Also known as== | ==Also known as== | ||
| − | *'''Generic | + | *'''Generic name:''' klofarabin |
*'''Brand names:''' Clolar, Evoltra, Evorabin | *'''Brand names:''' Clolar, Evoltra, Evorabin | ||
| Line 35: | Line 35: | ||
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
| + | [[Category:T-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
[[Category:FDA approved in 2004]] | [[Category:FDA approved in 2004]] | ||
Revision as of 22:54, 11 January 2020
General information
Class/mechanism: Purine analog, inhibits DNA synthesis and repair by inhibiting ribonucleotide reductase and competitively inhibiting DNA polymerases. It also causes apoptosis by disrupting the integrity of the mitochondrial membrane, triggering the release of cytochrome C and apoptosis-inducing factor, which are pro-apoptotic mitochondrial proteins.[1][2][3]
Route: IV, PO
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information can be found at the bottom of page 2 of the package insert[1]
- Clofarabine (Clolar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/28/2004: Initial FDA approval for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Also known as
- Generic name: klofarabin
- Brand names: Clolar, Evoltra, Evorabin